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Abstract
Background:  Systemic inflammation is associated with various complications in chronic
obstructive pulmonary disease including weight loss, cachexia, osteoporosis, cancer and
cardiovascular diseases. Inhaled corticosteroids attenuate airway inflammation, reduce
exacerbations, and improve mortality in chronic obstructive pulmonary disease. Whether inhaled
corticosteroids by themselves or in combination with a long-acting β2-adrenoceptor agonist
repress systemic inflammation in chronic obstructive pulmonary disease is unknown. The Advair
Biomarkers in COPD (ABC) study will determine whether the effects of inhaled corticosteroids
alone or in combination with a long-acting β2-adrenoceptor agonist reduce systemic inflammation
and improve health status in patients with chronic obstructive pulmonary disease.
Methods/Design:  After a 4-week run-in phase during which patients with stable chronic
obstructive pulmonary disease will receive inhaled fluticasone (500 micrograms twice daily),
followed by a 4-week withdrawal phase during which all inhaled corticosteroids and long acting β2-
adrenoceptor agonists will be discontinued, patients will be randomized to receive fluticasone (500
micrograms twice daily), fluticasone/salmeterol combination (500/50 micrograms twice daily), or
placebo for four weeks. The study will recruit 250 patients across 11 centers in western Canada.
Patients must be 40 years of age or older with at least 10 pack-year smoking history and have
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chronic obstructive pulmonary disease defined as forced expiratory volume in one second to vital
capacity ratio of 0.70 or less and forced expiratory volume in one second that is 80% of predicted
or less. Patients will be excluded if they have any known chronic systemic infections, inflammatory
conditions, history of previous solid organ transplantation, myocardial infarction, or
cerebrovascular accident within the past 3 months prior to study enrolment. The primary end-
point is serum C-reactive protein level. Secondary end-points include circulating inflammatory
cytokines such as interleukin-6 and interleukin-8 as well as health-related quality of life and lung
function.
Discussion: If inhaled corticosteroids by themselves or in combination with a long-acting β2-
adrenoceptor agonist could repress systemic inflammation, they might greatly improve clinical
prognosis by reducing various complications in chronic obstructive pulmonary disease.
Background
Chronic obstructive pulmonary disease (COPD) repre-
sents an increasing burden worldwide and is reported to
be the sixth leading cause of death in 1990 [1] and the
fourth in 2000 [2]. Discouragingly, by the year 2020, its
mortality rate will rank third, only behind stroke and
heart disease [1]. Although these figures are alarming,
they are likely to be gross underestimates of the true
health and economic burdens of COPD because COPD is
an important risk factor for other causes of morbidity and
mortality, including cardiovascular disorders and cancer
[3,4].
While the pathobiology of COPD has not been fully elu-
cidated, there is a growing recognition that systemic
inflammation may play a salient role in COPD progres-
sion and morbidity [5]. There is now a large body of data
that show systemic inflammation exists in stable COPD
and that the intensity of the inflammatory process relates
to the severity of the underlying disease [6]. Systemic
inflammation has been linked with the extra-pulmonary
manifestations in COPD including sudden deaths,
arrhythmias, strokes, myocardial infarction, and cancer
independent of confounding factors such as age and
smoking [4,6,7]. Additionally, in COPD, systemic inflam-
mation has been associated with diminished peripheral
muscle strength, reduced exercise endurance, workload,
and six-minute walk distance, poor health status, and
quality of life [8]. These data suggest that systemic inflam-
mation may be intrinsically involved in the downward
spiral in the health status of COPD patients. These data
also raise the possibility that treatments modulating sys-
temic inflammation could improve important health out-
comes in COPD.
Inhaled corticosteroids are powerful but non-specific anti-
inflammatory agents commonly used to treat patients
with COPD [9]. Recent studies indicate that although
inhaled corticosteroids do not alter the rate of decline in
lung function, they reduce bronchial hyperreactivity,
decrease the frequency of exacerbations, and slow the rate
of decline in the patient's health status [10,11]. A pooled
analysis of clinical trial data indicates they reduce mortal-
ity by ~25% relative to placebo over three to four years of
follow-up [12]. Interestingly, most of the beneficial signal
associated with inhaled corticosteroids was observed in a
subgroup of COPD patients with moderate to severe dis-
ease [12]. In patients with mild disease, there was no sur-
vival advantage. These findings are consistent with data
on exacerbations, which also demonstrate significant
reductions related to inhaled corticosteroids only in those
with moderate to severe disease [13]. Intriguingly,
biomarkers of lung and systemic inflammation are
increased in COPD patients with moderate to severe dis-
ease; patients with mild disease generally do not have
increased levels of inflammatory biomarkers [14].
Systemic corticosteroids reduce serum C-reactive protein
(CRP) and other circulating inflammatory cytokine levels
in COPD [15]. They also down regulate certain inflamma-
tory cells and cytokine levels in the airways of COPD
patients [16]. Whether inhaled steroids can reduce circu-
lating CRP levels in stable COPD is less certain. A pilot
randomized clinical trial of 41 patients with COPD indi-
cated that withdrawal of inhaled corticosteroids increased
serum CRP levels by ~70%; whereas a two week treatment
with inhaled fluticasone reduced CRP levels by ~50%
[15]. These findings are consistent with a recently pub-
lished observational study by Pinto-Plata and colleagues,
who found that users of inhaled corticosteroids had
serum CRP levels that were on average ~40% lower than
those among corticosteroid non-users [17].
Recent experimental evidence indicates that long-acting
β2-adrenoceptor agonists on their own can promote trans-
location of the glucocorticoid receptor complexes from
the cytosol to the nucleus, a process that is critical in
effecting the anti-inflammatory effects of corticosteroids
[18]. When long-acting β2-adrenoceptor agonists are
added to corticosteroids, the rate of glucocorticoid recep-
tor translocation may be accelerated [19]. Moreover, Zhu
and colleagues showed in a randomized controlled trial ofBMC Pulmonary Medicine 2006, 6:3 http://www.biomedcentral.com/1471-2466/6/3
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140 patients with moderate to severe COPD, that 12
weeks of treatment with salmeterol plus fluticasone
decreased tissue expression of tumor necrosis factor
(TNF)-α and interferon (IFN)-γ in the larger airways. They
also found that combination therapy decreased sputum
eosinophil (p = 0.03) and subepithelial mast cell counts
(p = 0.08) in the bronchial tissues [20,21]. Importantly,
these cellular changes were accompanied by a reduction
in the rate of exacerbations in the combination therapy
arm of the study. These results demonstrate that combina-
tion therapy decreases local inflammation in the lung, but
whether combination therapy reduces systemic inflam-
mation is still unknown.
Aims of the study
The primary aim of this randomized, placebo-controlled,
double-blind, multi-center clinical trial involving 11 cent-
ers in Western Canada is to determine whether inhaled
corticosteroids alone or in combination with a long acting
β2-adrenoceptor agonist reduce systemic inflammation in
stable COPD.
Specific objectives
This study will determine whether: 1) fluticasone alone or
in combination with salmeterol lowers CRP levels by at
least 30% below that achieved by placebo; and 2) combi-
nation therapy is better than fluticasone alone in reducing
CRP levels. We will also determine whether: 1) CRP reduc-
tions are associated with improved health-related quality
of life; 2) CRP reductions are associated with improved
forced expiratory volume in one second (FEV1), and 3)
inhaled fluticasone alone or in combination with salme-
terol can also reduce interleukin (IL)-6 and other pro-
inflammatory biomarkers in COPD.
Summary of the Trial Protocol Figure 1
Summary of the Trial Protocol. * Post bronchodilator values; all else will be pre-bronchodilator values. † Must be done prior to 
initiation of therapy and completion of therapy or during periods of acute exacerbation or infection. For those exacerbations 
or infections requiring oral steroids and/or antibiotics, patients will be asked to return 2 weeks after completing their acute 
exacerbation or infection treatment.
Phases  Run-In  Withdrawal  Active Treatment 
Weeks  1 2 3 4 5 6 7 8 9 10 11 12
Placebo 
Advair
®  500 ug bid 
Drugs Flovent
® 500ug bid  Withdrawal of Flovent
®
Flovent
®  500 ug bid 
Method of Allocation of 
Drugs 
All study patients 
(no blinding) 
All study patients 
(no blinding) 
Random allocation 
(Participants blinded to 
allocation) 
Venipuncture for blood 
analysis
†
♥ ♥ ♥ ♥     ♥ ♥ ♥ ♥     ♥ ♥ ♥ ♥    ♥ ♥ ♥ ♥
Spirometry  ♥ ♥ ♥ ♥*     ♥ ♥ ♥ ♥     ♥ ♥ ♥ ♥    ♥ ♥ ♥ ♥
SGRQ  ♥ ♥ ♥ ♥     ♥ ♥ ♥ ♥     ♥ ♥ ♥ ♥    ♥ ♥ ♥ ♥
Physical Examination  ♥ ♥ ♥ ♥             BMC Pulmonary Medicine 2006, 6:3 http://www.biomedcentral.com/1471-2466/6/3
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Methods/design
Overview of the study design
This trial is a double blind study comparing the effects of
inhaled fluticasone alone or in combination with salme-
terol against placebo on serum CRP levels in COPD. All
study participants will first undergo a run-in phase during
which they will be treated with fluticasone 500 mcg bid
for 4 weeks. This will be followed by a withdrawal phase
wherein all participants will be free of any inhaled corti-
costeroids or theophylline products for 4 weeks. After the
withdrawal phase, participants will be randomly assigned
to one of three arms: placebo; inhaled fluticasone (500
mcg bid); or inhaled fluticasone/salmeterol combination
(500/50 mcg bid). Randomization will be carried out cen-
trally according to a computer-generated sequence strati-
fied according to current smoking status with allocation
concealment in a 1 (placebo arm) to 2 (fluticasone arm)
to 2 (combination arm) distribution ratio. In this phase,
all participants and study personnel will be blinded to the
treatment assignment. This phase will last for 4 weeks. For
safety reasons, during severe exacerbations (i.e. those
requiring hospitalization or emergency visit for COPD),
the treating physician can break the "code" and place
study participants on medications needed to treat the
exacerbation (See Figure 1 for protocol summary)
Details of the run-in phase (4 weeks)
During this phase, all pulmonary medications with signif-
icant anti-inflammatory effects (e.g. inhaled corticoster-
oids, theophyllines, and leukotriene modifiers) will be
Management of Exacerbations during the Study Figure 2
Management of Exacerbations during the Study. Abbreviations: LABA, long-acting β2 adrenoceptor agonist; SGRQ, St. George's 
Respiratory Questionnaire.
Run-In Period                
Patient Taking fluticasone
Wash Out Period            
No steroids or LABA
Treatment Period           
Patient Taking Randomization Drug
Restart Treatment Phase
If Exacerbation or Infection
Continue with regular medications 
for 2 weeks post-treatment of 
exacerbation or infection 
Exacerbation/Infection Flow Sheet
Blood drawn if possible during 
Exacerbation/Infection
If Exacerbation or Infection
Blood drawn if possible during 
Exacerbation/Infection
Return to week 1(visit)
Restart Run-In Phase
Continue with regular medications 
for 2 weeks post-treatment of 
exacerbation or infection 
Exacerbation 
Treatment
Exacerbation 
Treatment
If Exacerbation or Infection
Blood drawn if possible during 
Exacerbation/Infection
Restart Run-In Phase
Continue with regular medications for 
2 weeks post-treatment of 
exacerbation or infection 
Exacerbation 
Treatment
Return to Week 7 Return to week 1(visit
Discontinue Study TreatmentBMC Pulmonary Medicine 2006, 6:3 http://www.biomedcentral.com/1471-2466/6/3
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discontinued. All participants will be maintained on
inhaled fluticasone (500 mcg bid; Flovent Diskus®, Glax-
oSmithKline Canada, Mississauga, ON). Short-acting β2-
adrenoceptor agonists (e.g. salbutamol) and/or anti-
cholinergic (ipratropium) will be allowed as rescue medi-
cations. Long-acting anticholinergic medication (i.e.
tiotropium) will also be permitted, if clinically indicated
as judged by the participants' attending physician. Long-
acting β2-adrenoceptor agonists, however, will be prohib-
ited.
Details of the withdrawal phase (4 weeks)
During this phase, inhaled fluticasone will be discontin-
ued and participants will not be allowed to take any other
inhaled corticosteroids, theophyllines or leukotriene
modifiers. Short-acting β2-adrenoceptor agonists (e.g.
salbutamol) and/or anti-cholinergic (ipratropium) inhal-
ers will be allowed as rescue medications. Long-acting
anticholinergic inhaler (i.e. tiotropium) will be permitted
as maintenance medication. Long-acting β2-adrenoceptor
agonists will be prohibited.
Details of the active treatment phase (4 weeks)
All participants will be randomized to one of 3 arms of the
trial: placebo (placebo diskus, GlaxoSmithKline Canada,
Mississauga, ON), inhaled fluticasone (500 mcg bid; Flov-
ent Diskus®, GlaxoSmithKline Canada, Mississauga, ON)
or inhaled fluticasone/salmeterol (500/50 mcg bid;
Advair Diskus®  GlaxoSmithKline Canada, Mississauga,
ON). Short-acting β2-adrenoceptor agonists (e.g. salbuta-
mol) and/or anti-cholinergic inhaler (ipratropium) will
be allowed as rescue medications. Long-acting anticholin-
ergic medication (i.e. tiotropium) will be allowed as
maintenance medication if clinically indicated as judged
by the participants' attending physician. Any other long-
acting β2-adrenoceptor agonists or inhaled corticosteroids
will not be allowed. As well, theophyllines or leukotriene
modifiers will not be permitted in this phase.
Exacerbations during the study period (see figure 2)
The participants will be instructed at enrollment to con-
tact the local study coordinator at the earliest opportunity
if their usual COPD symptoms (i.e. cough, dyspnea, spu-
tum production, or sputum color change) worsen, or if
they develop a fever (of unknown source), or active infec-
tions elsewhere (e.g. sinusitis). During exacerbations,
study coordinators will see the participants as soon as pos-
sible and will codify all exacerbations according to Pag-
giaro's criteria [22]. A mild episode is one that can be self-
managed by the patient at home, requiring only intensifi-
cation of current therapy; a moderate event is defined as
requiring antimicrobial and/or oral corticosteroid ther-
apy; and severe is defined as an event requiring admission
to a hospital or an emergency department. Treatment
decisions during exacerbations will be rendered by the site
(principal) investigators using the Canadian Thoracic
Society guidelines in consultation with the participants'
primary care provider [23]. Blood samples will be
obtained at the time of the exacerbation. If participants do
not or can not contact study coordinators during severe
exacerbations, the study coordinator will make every
attempt to obtain blood samples from the patients at the
time of their presentation to the emergency department or
hospital. For those who experience an exacerbation
requiring systemic corticosteroids and/or antimicrobials,
the study patients will be asked to return 2 weeks after
they finish their course of exacerbation medications at
which point their blood, spirometry, and health status
measurements will be collected. Once clinical stability is
achieved for a minimal of 2 weeks, the participants will
resume study participation in accordance to the schedule
published in figure 2.
Study participants
All participants must have a clinical diagnosis of COPD as
defined by the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) guidelines [24]. Spirometric crite-
ria will include a FEV1 of less than 80% of predicted with
an FEV1 to forced vital capacity (FVC) ratio of less than
0.70 (post-bronchodilator values). Additional inclusion
criteria will be a cigarette smoking history of more than 10
pack-years, clinical stability as defined by the absence of
exacerbations for at least 4 weeks, and age ≥ 40 years.
Exclusion criteria will be any known disseminated malig-
nancy, known chronic systemic infections or inflamma-
tory conditions (e.g. rheumatoid arthritis, systemic lupus
erythematosis, active sarcoidosis), previous solid organ
transplantation, myocardial infarction or cerebrovascular
accident within the past 3 months prior to study enrol-
ment, females of child-bearing age (i.e. must be amenor-
rheic for at least 12 months), participation in a drug trial
within the past 4 weeks prior to study enrolment, any sub-
ject who is unlikely to survive more than 6 months, recent
upper respiratory tract infection within the 4 weeks prior
to enrolment, unable to follow instructions, patients on
chronic oral theophyllines and unable or unwilling to
come off theophyllines for the study period, oral corticos-
teroids, or long-term immunosuppressive agents.
Laboratory & other measurements
Blood collection
During every visit (and in the case of an exacerbation and/
or infection according to Figure 2), study personnel will
take two 10 ml collection of blood from participants
through venipuncture using standard techniques. One
sample (~10 mls) will be collected in tubes that do not
contain an anti-coagulant and another in a tube that does
contain an anti-coagulant. The tubes without the anti-
coagulant will be allowed to clot for at least 30 minutes,
then centrifuged at ≥ 1500 × g for 15 min at room temper-BMC Pulmonary Medicine 2006, 6:3 http://www.biomedcentral.com/1471-2466/6/3
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ature and then divided into aliquots (at least 2 serum sam-
ples) using a sterile plastic transfer pipet. The serum
aliquots will be placed into supplied microtubes contain-
ing an anti-protease. Until used, the tubes containing the
anti-protease will be stored in a -20°C freezer. The serum
samples mixed with the anti-protease will be temporarily
stored in a portable cooler containing frozen gel-packs
and refrigerated at 4°C. Same-day shipment of the serum
samples will be organized by the participating site to the
central core laboratory located James Hogg iCAPTURE
Centre for Cardiovascular and Pulmonary Research, St.
Paul's Hospital, Vancouver, British Columbia, using a
courier service, guaranteeing arrival within 24 hours of
shipment. The tube with the anticoagulant will be tempo-
rarily stored in a portable cooler containing frozen gel-
packs and refrigerated (4°C) until same day shipment to
the central coordinating centre's laboratory in Vancouver
occurs. From these samples, the participants' serum C-
reactive protein (CRP) levels will be determined using a
commercially available high-sensitivity enzyme-linked
immunosorbent assay (ELISA) kits (Alpha Diagnostics,
San Antonion, Tx). Serum concentrations of IL-6, TNF-α,
and other inflammatory mediators will also be measured
using commercially available ELISA kits.
Spirometry
Spirometry will be performed for each participant at each
visit in accordance with the guidelines from the American
Thoracic Society [25]. A test session will consist of several
repeated FVC maneuvers. Each maneuver will require the
subject to take the deepest possible breath and exhale into
a spirometer as hard, fast, and completely as possible. The
spirometer will record the volume of air exhaled as a func-
tion of time. Each subject will perform at least three FVC
maneuvers. For a maneuver to be acceptable, it needs to
be a maximal exhalation free from cough, excessive hesi-
tation, leak, obstructed mouthpiece, variable effort, or
early termination. At the first visit, pre and post-bron-
chodilator measurements will be done. For follow-up vis-
its, only pre-bronchodilator values will be measured.
Health status measurements
During each visit, a disease-specific health measure, St.
George's Respiratory Questionnaire (SGRQ), will be
administered by the study co-ordinator at each site [26].
The scores for each section including symptom score (fre-
quency and severity), activity score (activities that cause or
are limited by breathlessness), and impact score (social
functioning, psychological disturbances resulting from
airways disease), as well as a total score will be calculated
using established methods [26].
Outcomes
Primary endpoint
The primary endpoint of the study is serum CRP level. We
anticipate that inhaled fluticasone alone or in combina-
tion with salmeterol will reduce CRP levels by at least 30%
below that achieved by placebo. We will also determine
whether combination therapy reduces CRP levels beyond
that achieved by fluticasone mono-therapy.
Secondary endpoints
The secondary endpoints will include: 1) changes in other
inflammatory mediators such as IL-6, TNF-α, and mono-
cyte chemotactic protein (MCP-1); 2) changes in SGRQ
scores; 3) changes in FEV1; and 4) rates of exacerbations
Statistics
Main analysis
For the primary analysis, we will compare the changes in
CRP at 4 weeks from baseline between those assigned to
inhaled fluticasone alone or in combination with salme-
terol and those assigned to placebo based on an intention-
to-treat principle. We will use between group t-tests to
determine whether the changes in CRP between the
groups are statistically significant and a mixed effects
model to adjust for any significant differences in the base-
line characteristics of the study participants across the
groups.
Secondary analyses
We will perform similar analysis on TNF-α, IL-6 and MCP-
1 (as well as other important inflammatory molecules).
We will use Pearson's correlation techniques (as well as
adjusted linear regression) to determine whether changes
in CRP levels correlate with changes in SGRQ scores. Pre-
vious studies indicate that SGRQ improves with flutica-
sone with or without salmeterol, independent of their
effects on FEV1 [10]. We hypothesize that SGRQ may cor-
relate with CRP.
Sample size calculation
We will enroll 250 participants with COPD for this study.
This will permit 100 participants to be assigned to flutica-
sone and combination treatment groups, respectively, and
50 participants will be exposed to a placebo during the
active treatment phase. We have calculated our sample
size based on the following assumptions: 1) we anticipate
that fluticasone relative to placebo will lower baseline
CRP levels by ~1.5 mg/L with standard deviation of 3.5
mg/L; 2) we will perform between group comparison of
CRP (from baseline) using independent two sample t-test
at alpha of 0.05 (two-tailed) and a power of ≥80%.
Ethical considerations
The protocol and procedures as described above have
received institutional approval from the University of Brit-BMC Pulmonary Medicine 2006, 6:3 http://www.biomedcentral.com/1471-2466/6/3
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ish Columbia/Providence Research Ethics Board, as well
as from all local institutional ethics review board of each
participating site. The funding for the study is from Glax-
oSmithKline (Mississauga, ON). The funding source has
no role in the design, conduct, analysis, interpretation, or
reporting of the study and will not have access to the raw
data. All data will be housed at the James Hogg iCAPTURE
Center in Vancouver, BC.
Discussion
In this paper, we have reported the background, the
rationale, and the study protocol for a unique multi-
center randomized controlled trial whose main outcome
is a biochemical measurement (i.e. CRP). The study will
test the hypothesis that inhaled corticosteroids alone or in
combination with a long-acting β2-adrenoceptor agonist
will reduce CRP levels in stable COPD patients. To our
knowledge, this is the first clinical trial in COPD whose
main outcome is serum CRP. Additionally, this study will
be able to determine the effects of these medications on
other relevant inflammatory biomarkers and likely pro-
vide a solid biological rationale for the clinical effects of
inhaled corticosteroids and combination therapy in
COPD.
There are certain limitations of this trial. Firstly, the study
will not measure any parameters of inflammation in the
lung. We decided against collecting biological samples
from the airways because: 1) a recently conducted and
published randomized controlled trial demonstrated that
combination therapy reduces airway inflammation
[20,21]; 2) there remains considerable amount of contro-
versy regarding the utility of exhaled condensates and
induced sputum in assessing airway inflammation in
COPD [28]; 3) more invasive measurements (e.g. bron-
choscopy) would have significantly reduced the projected
recruitment rate of participants, reducing the power of the
study to detect relevant differences in CRP; and 4) the pri-
mary focus of this study was to assess the effects of combi-
nation and steroid therapy on systemic inflammation.
Secondly, the study has a relatively short follow-up
period. We decided against a longer period of follow-up
for pragmatic reasons. In our previous pilot study, we
observed significant changes in CRP with inhaled corti-
costeroids after only 2 weeks of treatment [15]. Addition-
ally, we were concerned that follow-up longer than four
weeks would be associated with increased drop-out rates,
and exacerbations, reduced compliance with the study
medications, and changes in medications (both pulmo-
nary and nonpulmonary drugs) that may alter CRP levels.
Thirdly, we cannot be certain that changes in CRP levels
will necessarily result in significant changes in health out-
comes of COPD patients, though there is a body of indi-
rect evidence suggesting that they do [6,14,17]. Additional
work is needed in future studies to establish a causal link
between CRP and health outcomes in COPD.
In summary, the present study will determine whether
inhaled fluticasone alone or in combination with salme-
terol has any significant systemic anti-inflammatory
effects. Since systemic inflammation has been linked with
a variety of important complications in COPD including
peripheral muscle dysfunction, cachexia, cardiovascular
complications and cancer, if these medications do indeed
reduce systemic inflammation, this will provide an impor-
tant biological mechanism by which they improve health
outcomes in COPD. Additionally, this study will serve as
an important template for future studies, linking systemic
inflammation with clinical outcomes in COPD.
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